Bcell Design

Bcell Design company information, Employees & Contact Information

Explore related pages

Related company profiles:

Based in Illkirch-Graffenstaden (France), Bcell Design redefines the standards of diagnostic excellence by providing cutting-edge solutions that address the industry’s most pressing challenges. We specialize in developing, producing, and commercializing monoclonal antibodies with Fc human domains: a superior alternative to disease plasma. Our antibodies are designed to deliver unmatched sensitivity and specificity, ensuring consistent and reliable performance for diagnostic test manufacturers worldwide. What sets us apart? → Unparalleled accuracy: Our monoclonal antibodies raise the bar with precision and performance you can trust. → Reliability you can count on: Designed to eliminate variability and support consistent diagnostic outcomes. → A trusted partner: We collaborate closely with leading diagnostic companies to deliver tailored solutions for their unique needs. (Werfen, Virion\Serion, BioVendor, Diarect, Biomérieux, etc. → Innovative solutions: As pioneers in the field, we’re committed to advancing diagnostics through continuous research and development. → Exclusive patented technology: Our unique and patented approach to antibody development ensures that our solutions are not only innovative but also one-of-a-kind in the industry. Our products aren’t just materials, they’re a vital part of the solution, empowering manufacturers to build tests that drive accurate, timely, and life-changing decisions in healthcare. Follow us for: → Insights into the latest diagnostic innovations. → Stories of success from our global partners. → Opportunities to collaborate and raise the standard in diagnostics. 📩 Ready to elevate your diagnostics? Let’s connect to explore how we can work together.

Company Details

Employees
12
Founded
-
Address
850, Boulevard Sébastien Brant, Illkirch-Graffenstaden,grand Est 67400,france
Phone
+33 5 55 12 30 21
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Illkirch-Graffenstaden, Grand Est
Looking for a particular Bcell Design employee's phone or email?

Bcell Design Questions

News

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials - News-Medical

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials News-Medical

Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines | npj Vaccines - Nature

Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines | npj Vaccines Nature

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) - BioSpace

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) BioSpace

Built-in safeguard in B cell populations could impact vaccine design - Medical Xpress

Built-in safeguard in B cell populations could impact vaccine design Medical Xpress

KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma - OncLive

KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma OncLive

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial - Nature

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Nature

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans - ScienceDirect.com

Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans ScienceDirect.com

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma The Lancet

Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response - ScienceDirect.com

Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response ScienceDirect.com

Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies - Nature

Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies Nature

Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery - ScienceDirect.com

Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery ScienceDirect.com

B cell epitope prediction by capturing spatial clustering property of the epitopes using graph attention network - Nature

B cell epitope prediction by capturing spatial clustering property of the epitopes using graph attention network Nature

Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies - Nature

Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies Nature

Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages - Nature

Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages Nature

Integrating single-cell RNA and T cell/B cell receptor sequencing with mass cytometry reveals dynamic trajectories of human peripheral immune cells from birth to old age - Nature

Integrating single-cell RNA and T cell/B cell receptor sequencing with mass cytometry reveals dynamic trajectories of human peripheral immune cells from birth to old age Nature

Benchmarking and integrating human B-cell receptor genomic and antibody proteomic profiling - Nature

Benchmarking and integrating human B-cell receptor genomic and antibody proteomic profiling Nature

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 - Nature

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 Nature

Engaging an HIV vaccine target through the acquisition of low B cell affinity - Nature

Engaging an HIV vaccine target through the acquisition of low B cell affinity Nature

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial - Nature

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Nature

B cell memory: building two walls of protection against pathogens - Nature

B cell memory: building two walls of protection against pathogens Nature

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches - Nature

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Nature

B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies - ScienceDirect.com

B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies ScienceDirect.com

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma - Journal of Hematology & Oncology

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma Journal of Hematology & Oncology

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial - Nature

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial Nature

Conserved stromal–immune cell circuits secure B cell homeostasis and function - Nature

Conserved stromal–immune cell circuits secure B cell homeostasis and function Nature

Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies - Nature

Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies Nature

Long-term outcomes following CAR T cell therapy: what we know so far - Nature

Long-term outcomes following CAR T cell therapy: what we know so far Nature

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial - Nature

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial Nature

A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein - Nature

A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein Nature

Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens - ScienceDirect.com

Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens ScienceDirect.com

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages - ASM Journals

Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages ASM Journals

Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus - ScienceDirect.com

Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus ScienceDirect.com

Eliciting B cell immunity against infectious diseases using nanovaccines - Nature

Eliciting B cell immunity against infectious diseases using nanovaccines Nature

Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function - ScienceDirect.com

Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function ScienceDirect.com

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study - The Lancet

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study The Lancet

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial - Nature

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial Nature

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial - Nature

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Nature

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells - ScienceDirect.com

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells ScienceDirect.com

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma - Nature

Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma Nature

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis - Novartis

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis Novartis

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study - Nature

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study Nature

Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics - ScienceDirect.com

Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics ScienceDirect.com

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma - ScienceDirect.com

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma ScienceDirect.com

Programmable synthetic receptors: the next-generation of cell and gene therapies - Nature

Programmable synthetic receptors: the next-generation of cell and gene therapies Nature

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors - Science | AAAS

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors Science | AAAS

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation - ACS Publications

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation ACS Publications

Top Bcell Design Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant